1. 1500TiPeXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients. (23rd October 2018) Authors: Horn, L; Wu, Y-L; Reck, M; Wakelee, H; Liang, C; Harrow, K; Oertel, V; Mok, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 492OOsimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC. (25th November 2018) Authors: Ahn, M-J; Chiu, C-H; Cheng, Y; Han, J-Y; Goldberg, S B; Greystoke, A; Crawford, J; Zhao, Y; Huang, X; Johnson, M; Vishwanathan, K; Mendoza-Naranjo, A; Mok, T Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. (12th September 2018) Authors: Gadgeel, S; Peters, S; Mok, T; Shaw, A T; Kim, D W; Ou, S I; Pérol, M; Wrona, A; Novello, S; Rosell, R; Zeaiter, A; Liu, T; Nüesch, E; Balas, B; Camidge, D R Journal: Annals of oncology Issue: Volume 29:Number 11(2018) Page Start: 2214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. (26th March 2019) Authors: Peters, S; Reck, M; Smit, E F; Mok, T; Hellmann, M D Journal: Annals of oncology Issue: Volume 30:Number 6(2019) Page Start: 884 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗